Blood Test Shows High Accuracy for Early Ovarian Cancer Detection
A new study demonstrates the capability of a blood test in detecting ovarian cancer up to three years prior to diagnosis in prospectively collected samples.Â
A new study demonstrates the capability of a blood test in detecting ovarian cancer up to three years prior to diagnosis in prospectively collected samples.Â
The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
New automated workflow combines at-home sampling with robotic lab processing.
Two investigational diagnostics demonstrate significantly higher sensitivity than current CDC-recommended two-tier testing in Journal of Clinical Microbiology studies.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
The single-plex assay, for research use only, measures brain-derived phosphorylated tau 217 from plasma, serum, and dried blood spots without requiring cerebrospinal fluid collection.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.